The FDA has approved nirogacestat for the treatment of noncancerous but painful growths called desmoid tumors. The U.S. Food and Drug Administration (FDA) has approved nirogacestat (Ogsiveo) for adult patients with desmoid tumors that...
With a five-year survival rate of only 12.5%, any progress toward new therapeutic approaches for pancreatic cancer is welcomed by patients and their families. At present, increasingly complex chemotherapy regimens offer only marginal improvements...
Low rates of germline genetic testing in cancer patients means information that could affect treatment isn’t available.
The FDA has approved enzalutamide for non-metastatic prostate cancer that is sensitive to antiandrogen therapy. The U.S. Food and Drug Administration (FDA) has approved enzalutamide (Xtandi) for the treatment of non-metastatic castration-sensitive prostate cancer...
The FDA has approved capivasertib for the treatment of breast cancers with certain mutations. The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap), in combination with fulvestrant (Faslodex), for the treatment of...
The FDA has approved pembrolizumab for the first-line treatment of certain HER2-negative gastric and gastroesophageal junction cancers. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), in combination with a chemotherapy regimen...
The FDA has approved repotrectinib for certain patients with non-small cell lung cancer harboring a ROS1 mutation or rearrangement. The U.S. Food and Drug Administration (FDA) has approved repotrectinib (Augtyro) for the treatment of...
Stool test for signs of cancer, often collected at home, sometimes fails due to inadequate sampling, according to a study in the AACR Journal Cancer Epidemiology, Biomarkers & Prevention. About a tenth of the...
Our immune systems are equipped to recognize and destroy cancer cells—if they can find them, that is. And with tens of trillions of cells in the human body and the masterful hiding skills of...
Sun exposure is an occupational hazard around the globe, and a dormant virus can cause immunotherapy complications.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More